Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..
SYS-CON.TV
Today's Top SOA Links


Global Contraceptives Industry

NEW YORK, Dec. 10, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Contraceptives Industry
http://www.reportlinker.com/p087292/Global-Contraceptives-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

This report analyzes the worldwide markets for Contraceptives in US$ Million by the following Product Segments: Oral Contraceptives, Condoms, Implants/ Injections, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 123 companies including many key and niche players such as Ansell Limited, Condomi Health International GmbH, Bayer HealthCare Pharmaceuticals, Church & Dwight Co. Inc., Conceptus, Inc., Female Health Company, Fuji Latex Co Ltd., HLL Lifecare Limited, Johnson & Johnson, Janssen Pharmaceuticals Inc., Merck & Co., Inc., Okamoto Industries, Inc., Reckitt Benckiser Group Plc, Teva Pharmaceutical Industries Limited, Warner Chilcott plc, and Pfizer Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Oral Contraceptives I-3
Condoms I-3
Implants/Injections I-4
Other Contraceptives I-4

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
A Primer II-1
Contraceptives Market: Quick Facts II-2
Outlook II-2
Growth Drivers II-2
Challenges II-3
Impact of Recession: An Unequivocal Review II-3
Cooling Economy Induces Changes in Childbearing Trends II-3
Recession Adds Fuel to Cost/Affordability Challenge II-4
Rising Preference for Surgical Family Planning Procedures II-4
Contraceptives among Women: Scenario in the Developing World II-4
Table 1: Contraceptives Market in Developing World (2012):
Percentage Breakdown of Unintended Pregnancies by
Contraceptive Usage Trend (includes corresponding
Graph/Chart) II-5

Table 2: Capability of Modern Contraception in Mitigating
Mortality by Unintended Pregnancies in Developing Countries
(2012) (includes corresponding Graph/Chart) II-5
Other Trends & Issues II-5
Consolidation to Guide New Entrants into the Contraceptives
Market II-5
Increasing Awareness Over STDs to Create Additional Demand
for Condoms II-6
HIV Prevalence and Incidence Statistics II-6
Table 3: Global Prevalence of HIV Infection in 2010 by
Region (in Millions) (includes corresponding Graph/Chart) II-7

Table 4: Newly Infected HIV Population in 2010 by Region
(in Millions) (includes corresponding Graph/Chart) II-8



Table 5: Global HIV Related Deaths in 2010 by Region in
Millions (includes corresponding Graph/Chart) II-9



Table 6: Global HIV Prevalence among Adults and Youth (Male
and Female) By Region: 2010 II-10
Multifunctional Modern Contraceptives Make a Foray II-10
Skin Sprays: A Novel Way of Contraception II-10
Extensive Distribution Drives growth of Contraceptive Products II-11
Public Health Organizations Spur Condoms Use II-11
USAID Worldwide Shipments of Condoms and Other Contraceptives II-12
Table 7: USAID Shipments of Condoms and Contraceptives
Worldwide (2011): Percentage Share Breakdown of Unit
Shipments by Type - Male Condoms, Female Condoms and Oral
Contraceptives II-12



Table 8: USAID Shipments of Condoms and Other Contraceptives
Worldwide (2010): Percentage Share Breakdown of Value
Shipments by Region -Africa, Asia/Near East, Caribbean/Latin
America and Europe/Eurasia (includes corresponding
Graph/Chart) II-12



Table 9: Global USAID Shipments of Condoms and Other
Contraceptives (2010): Percentage Share Breakdown of Value
Shipments by Type -Condoms, Injectables, Orals, Implants and
IUDs (includes corresponding Graph/Chart) II-13



Table 10: USAID Shipments of Condoms and Other
Contraceptives Worldwide (2010): Percentage Share Breakdown
of Value Shipments by Program Type -Parastatal/Governmental,
Social Marketing, NGO and Research (includes corresponding
Graph/Chart) II-13
Latex Supply Woes Impact the Condoms Market II-13
Advertising for Contraceptives Acquires A Whole New Dimension II-14
Emergency Contraception Receives Encouragement from Government II-14
Manufacturers & Retailers Work in Sync to Accelerate Sales II-15
Competition in the Contraceptives R&D Market to Intensify II-15
Table 11: Global Contraceptives Market (2010): Percentage
Breakdown of Product Share in the R&D Pipeline by Stage of
Clinical Trial (includes corresponding Graph/Chart) II-15
Innovation Keeps the Fire Burning for the Condoms Market II-16
Generic & Biosimilar Contraceptive Products Gain Ground II-16
Generics Manufacturers II-16
OTC Hormonal Contraceptives - An Attractive Market II-16
Oral Contraceptives - A Painless Panacea for Prevention of
Unwanted Pregnancy II-17
R&D Companies & Generic Manufacturers - Developing Countries II-17
Commercial Success of R&D Brands Sustain Developmental
Programs in Developing Countries II-18
Challenges Facing Generic Contraceptive Products Manufacturers II-18

2. PRODUCT OVERVIEW II-19
Types of Contraception II-19
The Contraceptive Timeline II-19
By Function II-20
Barrier Contraceptives II-20
Characteristic Features of Barrier Methods II-20
Hormonal Contraceptives II-21
Prescription Contraceptives II-21
Oral Contraceptives II-21
Overview of Oral Contraceptives - Benefits vs. Risks II-21
Usage Levels of OCs in Worldwide Scenario II-22
Traditional and Modern II-22
Reversible and Permanent II-22
Birth Control Methods and their Use in Major Regions
Worldwide II-23
Contraception - Levels of Effectiveness II-24
Effectiveness Index of Contraceptive Measures II-24
Unmet Need for Contraception II-27
Segmental Analysis II-27
A. Condoms II-27
Overview II-27
Categories II-27
Latex Condoms II-27
Non-Latex Condoms II-27
Skin Condoms II-28
Polyurethane (PU) Condoms II-28
Comparison Between Polyurethane & Latex Condoms II-28
Male Condom - Effectiveness of Protection Against STDs II-29
Myths & Facts II-29
Selection & Effective Use of Condoms II-29
Highlights II-30
Growth Factors II-30
Factors Hindering Wide Spread Use of Condoms II-30
Measures Aimed at Increasing Usage II-31
Female Condoms II-31
Who are the Main Users? II-31
Reality - An Effective Female Condom II-32
B. Oral Contraceptives (OCs)/Pills II-32
A Peep into the Past II-32
Synthetic Oral Contraceptives II-33
Characteristic Features of Oral Contraceptives (OCs) II-33
Bayer Schering Pharma's "Yasmin": A Resounding Brand
Worldwide II-33
Advantages of Using OCs II-34
Effects of Long-Term Use of OCs II-34
Use of OCs/Pills - Myths & Facts II-35
Oral Contraceptives - Challenges & Strategies to Overcome
Problems II-35
Factors Associated with Failure of OCs/Pills II-36
Health Conditions to be Addressed when Using OCs II-36
Understanding Risks Associated with Use of OCs II-36
Cardiovascular Disease - A Major Side Effect of OCs II-37
Intake of OCs Result in High Blood Pressure II-37
Smoking Intensifies Respiratory Problems in Pill Users II-37
Age Related Complications Associated with the Direct Use
of OCs II-37
Relation Between OC and Cancer II-37
Depression Linked to Use of OCs II-38
OCs Increases Osteoporosis Risk at Later Stage II-38
OCs May Reduce Sex Drive II-38
Effects of Pill on Childbearing Capacity II-38
Visiting a Doctor - Highly Recommended in Case of Warning
Symptoms II-39
Emergency Contraception (EC) - A New Face of OCs II-39
Role of ECPs II-39
Effectiveness of ECP II-39
Different Types of EC Products II-40
Mini Pills II-40
RU486 - the French Abortion Pill II-41
Availability of Hormonal Contraceptives as OTC Drugs II-41
C. Injectable Contraceptives II-41
Depo-Provera II-41
Characteristic Features of Injectable Contraceptives II-42
Injectables - Challenges & Strategies to Overcome Problems II-42
D. Intrauterine Devices (IUDs)/Implants II-43
Product Categories II-43
CopperT 380A (ParaGard) II-43
Progesterone T (or Progestasert) II-43
Characteristic Features II-44
Benefits II-44
Side Effects II-44
Challenges & Strategies to Overcome Problems II-45
Long-term Reversible Contraceptive Implants II-45
Products II-45
Norplant II-45
Implanon II-46
Mirena II-46
Characteristic Features of Implantable Contraceptives II-46
Challenges & Strategies to Overcome Problems II-47
E. Spermicides II-47
Product Categories II-48
Benefits II-48
Drawbacks II-48
Contraceptive Foam II-48
Delfen Contraceptive Foam II-48
Contraceptive Cream or Jelly II-48
Encare Ovals II-48
Table 12: Effectiveness in Prevention of Pregnancy -
Condom and Spermicide, Condom Alone and Spermicide Alone
(includes corresponding Graph/Chart) II-49
F. Diaphragms II-49
G. Withdrawal & Douching II-50
H. Sterilization II-50
Tubal Ligation II-51
Reasons Behind Adoption II-51
Risk of Complications II-51
Types II-51
Abdominal Procedures II-52
Laparoscopy II-52
Mini-Laparotomy II-52
Laparotomy II-52
Vaginal Procedures II-52
Culdoscopy II-52
Colpotomy II-52
Hysterectomy - A High Risk Surgery II-53
Selective Tubal Occlusion Procedure (STOP) II-53
Vasectomy II-53
Method of Working II-53
Reasons Behind Adoption II-54
Risk of Complications II-54
I. Other Contraceptive Methods II-54
Contraceptive Sponges II-54
Today Sponge II-55
Characteristic Features of Today Sponge II-55
Table 13: Efficiency Rates of Today Sponge Based on
Usage for 12-Month Period (includes corresponding
Graph/Chart) II-56
Protectaid Sponge II-56
Characteristic Features of Protectaid Sponge II-57
Cervical Caps II-57
Pros and Cons of the Device II-57
Vaginal Contraceptive Film (VCF) II-58
Contraceptive Vaccine II-58
Ortho Evra Weekly Contraceptive Patch II-58
NuvaRing Monthly Vaginal Ring II-58

3. RESEARCH AND DEVELOPMENT II-59
Oral Contraceptive Minimizes Premenstrual Syndrome Symptoms
as per New Study II-59
Cause of Infertility - Not Associated with IUDs II-59
Presence of Estrogen in OCs Offers Protection from Colorectal
Cancer II-60
Hormonal Contraceptive Usage & Risk Associated with Certain STDs II-60
Use of Third Generation Ocs Increases Risk of Blood Clots II-60
High Risk of Deep Vein Thrombosis with Cyproterone-
Containing OCs II-60

4. ROLE OF UNITED NATIONS IN PROMOTING USE OF CONTRACEPTIVES II-61
Female Condoms Reach New Heights with Aid from UNAIDS II-61
Donor Support for Contraceptive Commodity II-61
Table 14: Total Cost of Contraceptives and Condoms:
2000-2010 (In US$ Million) (includes corresponding
Graph/Chart) II-61
Unmet Need II-62
Urgent Need for Use of Modern Contraceptives II-62
Table 15: Penetration of Modern Contraceptives in Developing
Regions for Women in Reproductive Age by Need (2011)
(includes corresponding Graph/Chart) II-62

Table 16: Usage of Modern Contraceptive by Women in
Developing Countries (2012): Percentage Breakdown by Type
(includes corresponding Graph/Chart) II-63
Use of Modern Contraceptives Grows in Developing Regions II-63
Table 17: Estimated Numbers of Contraceptive Users in
Developing Nations: 2000-2015 (In Millions) (includes
corresponding Graph/Chart) II-63

Table 18: Percentage Penetration of Modern Contraceptives by
Married Women by Region/ Country (2011) (includes
corresponding Graph/Chart) II-64

Table 19: Capability of Modern Contraception in Mitigating
Mortality by Unintended Pregnancies in Developing Countries
(2012) (includes corresponding Graph/Chart) II-64
Difference in Usage of Oral contraceptives in Developed and
Developing World II-65
Prevalence of Contraceptive Methods II-65
Table 20: Worldwide Contraceptives Market: Estimated Number
of Users (2015 & 2025) - Asia, Latin America and Africa (In
Millions) (includes corresponding Graph/Chart) II-65

Table 21: Worldwide Contraceptive Market: Prevalence in
Women (2000-2025) - Percentage Share by Asia, Latin America
and Africa (includes corresponding Graph/Chart) II-66
United Nations Population Fund (UNFPA) II-66
UNFPA Gets Aid from Britain to Help Developing World II-67
Rise in Cost of Providing Contraceptives II-68
Future Trends Worldwide II-68

5. NEW PRODUCT INTRODUCTIONS/ INNOVATIONS II-69
Watson Pharmaceuticals Introduces Vestura an Oral Contraceptive II-69
Ansell Unveils SKYN® Condom in Brazil and China II-69
Vystar® and Ritex Gummiwarenfabrik to Launch Ritex Silver-
Light Condoms II-69
Bayer HealthCare Pharmaceuticals Introduces Qlaira® Oral
Contraceptive II-69
The Female Health Offers La Luna Female Condoms in Israel II-69
Merck & Co Introduces NEXPLANON 68mg II-70
Watson Pharmaceuticals Introduces Generess™ Fe II-70
WomanCare Global Includes Essure® to Product Portfolio II-70
LifeStyles Introduces SKYN® Large II-70
Acme Brasil Introduces Condoms under the Unique by Natural
Sensation® II-71
Conceptus Launches Essure FlexPayTM Financial Assistance Plan II-71
Lupin Pharmaceuticals Introduces Generic Femcon Fe Chewable
Tablets in US II-71
Hyundai Pharm and HRA Pharma Roll Out ellaOne in South Korea II-71
Futura Develops CSD500 II-72

6. PRODUCT INNOVATIONS/INTRODUCTIONS IN THE RECENT PAST - A
PERSPECTIVE BUILDER II-73
Watson Pharmaceuticals Rolls Out ella Oral Emergency
Contraceptive II-73
HLL Lifecare to Launch Pan Flavoured Condoms II-73
Glenmark Generics Receives USFDA Approval for Norethindrone
Tablets II-73
HLL Lifecare to Introduce Moods in Australian Markets II-73
Organon Releases Contraceptive NuvaRing II-74
HRA Pharma Unveils ellaOne II-74
Bayer Introduces Qlaira New Oral Contraceptive II-74
Durex Introduces Avanti Bare™ II-74
Teva to Introduce Tri-Lo Sprintec II-74
Teva Announces Launch of Topiramate Tablets II-74
Duramed Releases LoSEASONIQUE II-75
Uganda Health Marketing Group Rolls Out NewFem, A New
Contraceptive Pill II-75
TTK LIG to Unveil Durex Jeans Condoms II-75
Teva Pharmaceutical Industries Receives Approval for Plan B
One-Step Emergency Contraceptive II-75
Cupid Limited to Unveil Cost-effective Female Condoms II-76
Bayer Schering Pharma Launches Qlaira® II-76
Watson Laboratories Secures USFDA Approval for Plan B OTC
Generics II-76
Organon Launches Vaginal Contraceptive Ring II-76



7. RECENT INDUSTRY ACTIVITY II-77
Ansell Takes Over Trelleborg Protective Products Operations II-77
Bayer HealthCare Partners with USAID to Launch Microgynon Fe
Contraceptive II-77
DKT International to Distribute Contraceptives in Ghana II-77
Conceptus Obtains FDA Approval for Inclusion of 10-Year Data
for Essure® Procedure II-77
Conceptus Secures FDA Approval for Label Changes Related to
Compatible Usage of NovaSure® with Essure II-78
Lupin Receives FDA Approval for Generic Variant of Ortho Tri
-cyclen Lo Oral Contraceptive II-78
Glenmark Generics US Receives FDA Approval for Ethinyl
Estradiol and Norgestimate Tablets II-78
Bayer HealthCare Pharmaceuticals Receives FDA Approval for
NataziaTM II-79
Teva Receives FDA Approval for Quartette™, An Oral
Contraceptive for Females II-79
Agile Therapeutics Receives FDA Approval for AG200-15,
Contraceptive Patch II-79
The Female Health Company Established Two New Production
Lines In Malaysia II-79
Glenmark Receives Approval for its Viorele, an Oral
Contraceptive for Women II-79
Watson Pharmaceuticals Receives USFDA Approval for Beyaz II-80
Bayer Files for EU Approval for the Company's Birth Control
Patch II-80
J&J 's Ortho Evra, Birth Control Patch Receives FDA Approval II-80
Pfizer Recalls Norgestrel/Ethinyl Estradiol Tablets and Lo/
Ovral®-28 Tablets from US II-80
Savanna East Africa Acquires Kenyan Condom Producer in Kenya II-81
Ansell Takes Over Minority Stake in Yulex II-81
Ortho-McNeil and PriCara to Operate Under Janssen
Pharmaceuticals II-81
Conceptus Acquires Distribution Rights to Essure Device II-81
Sosei Receives Approval for NorLevo Tablets by Japan Ministry
of Health, Labour and Welfare II-82
Starpharma Holdings Inks Licensing Agreement with Ansell II-82
Starpharma Holdings Enters into Agreement with Okamoto II-82
Female Health Company Receives Supply Order from British
Government II-82



8. CORPORATE ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER II-83
WomanCare Global Acquires Roselle and Optinor from Icon II-83
Teva Signs Deal to Acquire Theramax II-83
Ferring Pharmaceuticals Purchases Lysteda from Xanodyne
Pharmaceuticals II-83
NextPharma Technologies Expands Waltrop Semi-Solids Hormones
Facility II-84
Reckitt Benckiser Acquires SSL International II-84
Warner Chilcott and Lupin Pharmaceuticals Ink Settlement
Agreement II-84
FHC Bags Order to Supply 3.5 Million FC2 Female Condoms for
2010 World Cup in South Africa II-84
SSL Acquires Majority Stake in BLBV II-85
Columbia Laboratories Inks Definitive Agreement with Watson
Pharmaceuticals II-85
Piramal Healthcare Signs Definitive Agreement with Cipla II-85
Watson Pharmaceuticals to Market HRA Pharma's Emergency
Contraceptive II-86
Lupin to Establish Three New Production Facilities II-86
Pfizer to Purchase Wyeth II-86
Ansell Healthcare Signs Agreement with NYC Department of
Health and Mental Hygiene II-86
Teva Pharmaceutical Industries' Yaz Receives FDA Approval II-87
Teva Pharmaceutical Industries' Yaz Receives Marketing
Approval from FDA II-87
Watson Pharmaceuticals, Warner Chilcott Collaborate for Femring II-87
Watson Pharmaceuticals Inks Agreement with Warner Chilcott
for WC3026 II-87
Merck Merges with Schering-Plough II-88
Vystar Inks Agreement with Centrotrade Minerals and Metals
and Centrotrade Deutschland II-88
Mayer Laboratories Signs Agreement with Alvogen Group II-88
Hypermarcas Acquires Inal II-88
Sosei Inks Distribution Agreement with ASKA Pharmaceuticals II-88
Sanofi-Aventis to Construct Plant in Brazil II-89
Durex Chinese Plant Starts Production II-89
Patheon Expands Toronto Plant II-89
Female Health Co Receives FDA Approval for Cheaper Female Condom II-89



9. FOCUS ON SELECT GLOBAL PLAYERS II-90
Ansell Limited (Australia) II-90
Condomi Health International GmbH (Germany) II-90
Bayer HealthCare Pharmaceuticals (Germany) II-90
Church & Dwight Co., Inc. (US) II-91
Conceptus Inc (US) II-91
Female Health Company (US) II-91
Fuji Latex Co Ltd (Japan) II-92
HLL Lifecare Limited (India) II-92
Johnson & Johnson (US) II-93
Janssen Pharmaceuticals Inc. (US) II-93
Merck & Co., Inc (USA) II-93
Okamoto Industries Inc (Japan) II-94
Reckitt Benckiser Group Plc (UK) II-94
Teva Pharmaceutical Industries Limited (Israel) II-94
Warner Chilcott plc (Ireland) II-95
Pfizer Inc (USA) II-95



10. GLOBAL MARKET PERSPECTIVE II-96
Table 22: World Recent Past, Current & Future Analysis for
Contraceptives by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) II-96



Table 23: World Historic Review for Contraceptives by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) II-97



Table 24: World 15-Year Perspective for Contraceptives by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets for Years 2004, 2011
& 2018 (includes corresponding Graph/Chart) II-98



Table 25: World Recent Past, Current & Future Analysis for
Oral Contraceptives by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) II-99



Table 26: World Historic Review for Oral Contraceptives by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) II-100



Table 27: World 15-Year Perspective for Oral Contraceptives by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets for Years 2004, 2011
& 2018 (includes corresponding Graph/Chart) II-101



Table 28: World Recent Past, Current & Future Analysis for
Condoms by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) II-102



Table 29: World Historic Review for Condoms by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2004 through 2009 (includes corresponding Graph/Chart) II-103



Table 30: World 15-Year Perspective for Condoms by Geographic
Region - Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World Markets for Years 2004, 2011 & 2018
(includes corresponding Graph/Chart) II-104



Table 31: World Recent Past, Current & Future Analysis for
Implants/Injections by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) II-105



Table 32: World Historic Review for Implants/Injections by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) II-106



Table 33: World 15-Year Perspective for Implants/ Injections
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets for Years
2004, 2011 & 2018 (includes corresponding Graph/Chart) II-107



Table 34: World Recent Past, Current & Future Analysis for
Other Contraceptives by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2010 through 2018
(includes corresponding Graph/Chart) II-108



Table 35: World Historic Review for Other Contraceptives by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) II-109



Table 36: World 15-Year Perspective for Other Contraceptives
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets for Years
2004, 2011 & 2018 (includes corresponding Graph/Chart) II-110


III. MARKET



1. THE UNITED STATES III-1
A.Market Analysis III-1
Outlook III-1
Restraints III-1
Are Women's Reproductive Rights Getting Axed on the New
Health Care Bill? III-1
Medicaid Coverage For Family Planning III-2
Regulations Encouraging Access to Emergency Contraceptives III-2
Major Market Trends III-3
Generics Pitted Against Branded in the Oral Contraceptives
Market III-3
Changing Consumer Demographics III-3
Relentless Promotional Programs Drive Home the Point III-3
Use of Intimacy Products on the Rise III-4
Generics Ransack the Branded Market III-4
Condoms - A 'Fun, Inviting and Pleasurable' Way to Healthy
Life and Lifestyle III-4
Market Share Statistics III-5
Table 37: Leading Players in the US Male Contraceptives
Market (2011): Percentage Breakdown of Sales for Church and
Dwight Co., Reckitt Benckiser, Ansell, Global Protection,
Mayer Labs, Majestic Drug Co., Private label and Others
(includes corresponding Graph/Chart) III-5



Table 38: US Market for Condoms by Leading Players (2011):
Market Share Breakdown for Church & Dwight, Reckitt
Benckiser, Ansell America, and Others (includes
corresponding Graph/Chart) III-5



Table 39: Leading Brands in the US Condom Market (2011):
Percentage Share Breakdown by Sales (includes
corresponding Graph/Chart) III-6



Table 40: US Condoms Market: Percentage Breakdown of Dollar
Sales by Product Type for the Year Ended January 2006
(includes corresponding Graph/Chart) III-6



Table 41: Leading Female Contraceptive Manufacturers in the
US (2011): Percentage Breakdown of Market Share for Duramed
Pharmaceuticals, Watson Pharmaceuticals, Coldwell Consumer
Health, Apothecus and Others (includes corresponding
Graph/Chart) III-6



Table 42: Leading Brands in the Female Contraceptives
Market in the US (2009): Percentage Breakdown of Market
Share for Plan B, VCF, Ortho Options Conceptrol, Encare,
Ortho Options Gynol II and Others (includes corresponding
Graph/Chart) III-7
Noticeable Shift in Retail Marketing Techniques III-7
Rising Use of Condoms Amongst Teenagers III-7
Changing Attitudes and Perceptions Drive Market Sales III-8
Table 43: Contraceptive Usage (Methods) and Non-Usage
among Women Aged 15-44 Years in the US (2011) (includes
corresponding Graph/Chart) III-8
Elimination of Co-pays to Boost Contraceptive Sales III-9
Pill Continues to be One of the Most Popular Forms of
Contraception III-9
Table 44: Usage Trends of Select Contraceptive Methods
Among Women Aged 15-44 Years in the US (2011): Percentage
Breakdown by Marital Status (includes corresponding
Graph/Chart) III-10



Table 45: Female Contraception in the US (2011): Percentage
Breakdown of Usage of Pill or Sterilization Method by Age
Group (includes corresponding Graph/Chart) III-10

Table 46: Leading Birth Control Pill Brands in the US
(2011): Percentage Breakdown of Market Share for Yaz,
Tri-Sprintec, Ocella, Loestrin 24 Fe, NuvaRing, Sprintec,
Trinessa, Aviane, Ortho Tri-Cyclen Lo and Others
(includes corresponding Graph/Chart) III-11
Oral Contraceptives Gain Ground in the US III-11
Table 47: Leading Birth Control Pill Manufacturers in the
US (2010): Percentage Breakdown of Market Share for Duramed
Pharmaceuticals, Watson Pharmaceuticals Inc., Caldwell
Consumer Health L.L.C., Apothecus Inc. and Others
(includes corresponding Graph/Chart) III-11
Oral Contraceptives and its Shades of Grey III-12
Marketing Efforts Aimed at Influencing Female College
Students III-12
Condoms Continuing Canter III-12
Drug Stores Remain the Choice for Contraceptive Needs III-12
Trade Class Statistics III-13
Oral Contraceptives - Unanimously the Choice of American Women III-13
Table 48: Contraceptive Features Preferred by Women in US
(includes corresponding Graph/Chart) III-13
Health Facts III-14
Rising Use of Oral Contraceptives III-14
Abortion Control Drugs & Methods III-14
Medical Abortion III-15
a. Mifepristone - A Medical Breakthrough III-15
b. Methotrexate III-15
Expanding the Use & Availability of EC Drugs III-15
Pharmacies Sell ECPs III-15
Demographics III-16
Facts and Figures III-16
Sales of Contraceptives (Male & Female) - Family Planning
Category III-16
Insurance Coverage for Contraceptives Still in Contest III-16
Strategic Corporate Developments III-17
Product Innovations/Launches III-19
Key Players III-21
B.Market Analytics III-25
Table 49: US Recent Past, Current & Future Analysis for
Contraceptives by Product Segment - Oral Contraceptives,
Condoms, Implants/Injections and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-25



Table 50: US Historic Review for Contraceptives by Product
Segment - Oral Contraceptives, Condoms, Implants/Injections
and Others Markets Segments Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2004 through
2009 (includes corresponding Graph/Chart) III-26



Table 51: US 15-Year Perspective for Contraceptives by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Contraceptives, Condoms, Implants/Injections and Others
Markets for 2004, 2011 & 2018 (includes corresponding
Graph/Chart) III-27



2. CANADA III-28
A.Market Analysis III-28
Scenario III-28
Outlook III-28
Condoms Market III-28
Immucon Obtains US Patent for Male Contraceptive Technology III-28
B.Market Analytics III-29
Table 52: Canadian Recent Past, Current & Future Analysis
for Contraceptives by Product Segment - Oral
Contraceptives, Condoms, Implants/Injections and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) III-29



Table 53: Canada Historic Review for Contraceptives by
Product Segment - Oral Contraceptives, Condoms,
Implants/Injections and Others Markets Segments
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) III-30



Table 54: Canadian 15-Year Perspective for Contraceptives by
Product Segment - Percentage Breakdown of Dollar Sales Oral
Contraceptives, Condoms, Implants/Injections and Others
Markets for 2004, 2011 & 2018 (includes corresponding
Graph/Chart) III-31



3. JAPAN III-32
A.Market Analysis III-32
Outlook III-32
Market for Oral Contraceptives Yet to Take Off III-32
Innovation Expected to Drive Sales III-32
Major Issues and Trends III-32
Domestic Products Dominate the Market III-32
Health Care Institutions Remain Main Distribution Channels III-33
Market Issues III-33
Compulsory Labeling of Contraceptives III-33
Impact of Legalization of Oral Contraceptives III-33
Late Approval for Use of OCs in Japan III-33
Factors Hindering Widespread Use of OCs III-34
Condoms Market III-34
Key Players III-34
B.Market Analytics III-36
Table 55: Japanese Recent Past, Current & Future Analysis
for Contraceptives by Product Segment - Oral
Contraceptives, Condoms, Implants/Injections and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) III-36



Table 56: Japanese Historic Review for Contraceptives by
Product Segment - Oral Contraceptives, Condoms,
Implants/Injections and Others Markets Segments
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) III-37



Table 57: Japanese 15-Year Perspective for Contraceptives by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Contraceptives, Condoms, Implants/Injections and Others
Markets for 2004, 2011 & 2018 (includes corresponding
Graph/Chart) III-38



4. EUROPE III-39
A.Market Analysis III-39
Outlook III-39
Condoms Market III-39
Prejudices Pertaining to Birth Control Pills III-39
Condoms and Other Contraceptives Market III-39
Table 58: USAID Shipments of Condoms and Other
Contraceptives to Europe and Eurasia (2010): Percentage
Share Breakdown of Value Shipments by Type -Condoms,
Orals, Female Condoms, IUDs and Injectables (includes
corresponding Graph/Chart) III-39
B.Market Analytics III-40
Table 59: European Recent Past, Current & Future Analysis
for Contraceptives by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-40



Table 60: European Historic Review for Contraceptives by
Contraceptives by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) III-41



Table 61: European 15-Year Perspective for Contraceptives by
Geographic Region - Percentage Breakdown of Dollar Sales
for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2004, 2011 & 2018 (includes
corresponding Graph/Chart) III-42



Table 62: European Recent Past, Current & Future Analysis
for Contraceptives by Product Segment - Oral
Contraceptives, Condoms, Implants/Injections and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) III-43



Table 63: European Historic Review for Contraceptives by
Product Segment - Oral Contraceptives, Condoms,
Implants/Injections and Others Markets Segments
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) III-44



Table 64: European 15-Year Perspective for Contraceptives by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Contraceptives, Condoms, Implants/Injections and Others
Markets for 2004, 2011 & 2018 (includes corresponding
Graph/Chart) III-45



4a. FRANCE III-46
A.Market Analysis III-46
Outlook III-46
Condoms Market III-46
B.Market Analytics III-47
Table 65: French Recent Past, Current & Future Analysis for
Contraceptives by Product Segment - Oral Contraceptives,
Condoms, Implants/Injections and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-47



Table 66: French Historic Review for Contraceptives by
Product Segment - Oral Contraceptives, Condoms,
Implants/Injections and Others Markets Segments
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) III-48



Table 67: French 15-Year Perspective for Contraceptives by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Contraceptives, Condoms, Implants/Injections and Others
Markets for 2004, 2011 & 2018 (includes corresponding
Graph/Chart) III-49



4b. GERMANY III-50
A.Market Analysis III-50
Outlook III-50
German Women Record Highest Usage Rate of Contraceptive Pill III-50
Condoms Market III-50
Key Players III-50
B.Market Analytics III-52
Table 68: German Recent Past, Current & Future Analysis for
Contraceptives by Product Segment - Oral Contraceptives,
Condoms, Implants/Injections and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-52



Table 69: German Historic Review for Contraceptives by
Product Segment - Oral Contraceptives, Condoms,
Implants/Injections and Others Markets Segments
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) III-53



Table 70: German 15-Year Perspective for Contraceptives by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Contraceptives, Condoms, Implants/ Injections and
Others Markets for 2004, 2011 & 2018 (includes
corresponding Graph/Chart) III-54



4c. ITALY III-55
A.Market Analysis III-55
Outlook III-55
B.Market Analytics III-56
Table 71: Italian Recent Past, Current & Future Analysis
for Contraceptives by Product Segment - Oral
Contraceptives, Condoms, Implants/ Injections and Others
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) III-56

Table 72: Italian Historic Review for Contraceptives by
Product Segment - Oral Contraceptives, Condoms,
Implants/Injections and Others Markets Segments
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) III-57



Table 73: Italian 15-Year Perspective for Contraceptives by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Contraceptives, Condoms, Implants/Injections and Others
Markets for 2004, 2011 & 2018 (includes corresponding
Graph/Chart) III-58



4d. THE UNITED KINGDOM III-59
A.Market Analysis III-59
Outlook III-59
Overview III-59
UK Contraceptives Market Sails Through Recession III-59
Changing Societal Trends III-60
Innovations: Need of the Hour III-60
Availability of Contraceptives III-60
Contraceptive Injections III-60
Emergency Contraception (EC) III-61
Barrier Contraceptives III-61
Major Trends and Issues III-61
Hormone Based Products Overtake Barrier Products III-61
Condoms Still Find Immense Favor in Britain III-61
Table 74: Condom Usage Trends in the UK (2012): Breakdown
of Usage Rate by Age and Gender (includes corresponding
Graph/Chart) III-62
Value of Condoms Declines Even as Volume Sales Increases III-62
Role of Pharmacies in Improving Availability of Condoms
and EC Drugs III-62
Regulatory Environment III-62
CEN Standards III-62
Advertising and Promotion III-63
Hormone-Based Contraceptives Restricted by Legislation III-63
B.Market Analytics III-63
Table 75: UK Recent Past, Current & Future Analysis for
Contraceptives by Product Segment - Oral Contraceptives,
Condoms, Implants/Injections and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-63



Table 76: UK Historic Review for Contraceptives by Product
Segment - Oral Contraceptives, Condoms, Implants/Injections
and Others Markets Segments Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2004 through
2009 (includes corresponding Graph/Chart) III-64



Table 77: UK 15-Year Perspective for Contraceptives by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Contraceptives, Condoms, Implants/Injections and Others
Markets for 2004, 2011 & 2018 (includes corresponding
Graph/Chart) III-65



4e. SPAIN III-66
A.Market Analysis III-66
Current & Future Analysis III-66
Outlook III-66
B.Market Analytics III-67
Table 78: Spanish Recent Past, Current & Future Analysis for
Contraceptives by Product Segment - Oral Contraceptives,
Condoms, Implants/Injections and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-67



Table 79: Spanish Historic Review for Contraceptives by
Product Segment - Oral Contraceptives, Condoms,
Implants/Injections and Others Markets Segments
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2004 through 2009 (includes corresponding
Graph/Chart) III-68



Table 80: Spanish 15-Year Perspective for Contraceptives by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Contraceptives, Condoms, Implants/Injections and Others
Markets for 2004, 2011 & 2018 (includes corresponding
Graph/Chart) III-69



4f. RUSSIA III-70
A.Market Analysis III-70
Outlook III-70
B.Market Analytics III-71
Table 81: Russian Recent Past, Current & Future Analysis for
Contraceptives by Product Segment - Oral Contraceptives,
Condoms, Implants/Injections and Others Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-71



Table 82: Russian Historic Review for Contraceptives by
Product Segment - Oral Contraceptives, Condoms, Implants/
Injections and Others Markets Segments Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2004 through 2009 (includes corresponding Graph/Chart) III-72

Table 83: Russian 15-Year Perspective for Contraceptives by
Product Segment - Percentage Breakdown of Dollar Sales for
Oral Contraceptives, Condoms, Implants/Injections and Others
Markets for 2004, 2011 & 2018 (includes corresponding
Graph/Chart) III-73



4g. REST OF EUROPE III-74
A.Market Analysis III-74
Outlook III-74
Modern Contraceptives Usage in Eastern European Markets III-74
Table 84: Usage Rates of Modern and Traditional
Contraceptives in Developed and Developing Markets in
Europe (2010) III-75
Regional Briefs







To order this report:
Drug_and_Medication Industry:
Global Contraceptives Industry

__________________________
Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021

SYS-CON Featured Whitepapers
ADS BY GOOGLE